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IV 
Pharmacogenomics seeks a detailed understanding of inherited drug response. Building on 
earlier studies linking race to differentiated outcome, it is anticipated to provide, through the 
use of racial classification, substantial therapeutic benefits. However, the reliance on race 
remains controversial and contested. A survey of the academic literature reveals a broad 
spectrum of views on the scientific legitimacy, value and import of using the notion of race 
in genomics research. The purpose of this qualitative inquiry was to identify the views of 
genomics researchers concerning the use of racial classification in pharmacogenomics 
research. Thirteen semi-directed interviews were conducted with researchers from the 
Montreal area who self-identified with minority populations. The researchers were 
cautiously optimistic about such "doubled-edged" research. They had a favorable view of 
race-specific therapeutics and believed that pharmacogenomics would improve health 
outcomes for racial populations in a context of health disparities. Sensitized to racism and 
potential abuses, they nevertheless felt conflicted by the sensitive nature of racially 
categorized research results. The findings inform recommendations that have consequences 
for subjects of research, the professional practice of researchers as weIl as for efforts to 
increase reciprocity between researchers and the public. 
Keywords: pharmacogenomics, race, genetic research, research ethics, professional 
duties, drugs, BiDil 
La pharmacogénomique cherche à comprendre la relation entre la constitution génétique et 
la réponse à un traitement médicamenteux. Des études ayant associé la race au métabolisme 
de médicament, l'utilisation de la classification raciale en pharmacogénomique est anticipée 
d'amener des bénéfices thérapeutiques importants. Toutefois, cette utilisation de la notion 
de la race en génomique s'avère controversée et contestée. Une revue de la littérature révèle 
une diversité d'attitudes concernant la légitimité scientifique et les conséquences de telles 
recherches. Le but de ce projet est d'identifier les attitudes de chercheurs en génomique 
envers la recherche en pharmacogénomique impliquant la race. Treize entrevues semi-
dirigées ont été réalisées auprès de chercheurs montréalais qui s'identifient comme membres 
de populations minoritaires. Les chercheurs se prononçaient comme optimistes mais 
prudents vis-à-vis une recherche qu'ils estimaient à «double-tranchant ». Ds avaient des 
opinions positives de médicaments à prescription raciale et croyaient que ceux-ci 
amélioreraient la santé de populations raciales. Tout de fois, très conscients du racisme et 
des sévices potentiels, ils étaient en conflit avec les résultats de recherche de nature 
impliquant la classification raciale. Ces résultats nous mènent à élaborer des 
recommandations qui ont des conséquences pour les sujets de recherche, la démarche 
professionnelle des chercheurs ainsi que les efforts d'augmenter la réciprocité entre la 
communauté scientifique et le public. 
Mots clé : pharmacogénomique, race, éthique de la recherche, responsabilités 
professionnelles, recherche en génétique, médicaments, BiDil. 
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• INTRODUCTION 
Mired in as much fanfare as the y are in controversy, advances in the field of 
genomics provide researchers with new ways of understanding the human organism. 
Genomics is the scientific discipline that concems the genome and the entirety of its 
function. 1 Vpon leaming that one of these advances was shaping up to be 
'personalized' genomic medicine prescribed along racial lines, my first inclination 
was to want to know why this appealed to scientists. This effort represents the 
intersection of my interests: the role of genomics professionals, the processes 
involved in pharmaceutical research and development and issues of social justice as 
they pertain to bioethics. 
Pharmacogenomics seeks a detailed understanding of inherited drug 
response, i.e. the relation between a patient's individu al genetic makeup and her 
response to medication. Building on earlier studies linking race or ethnicity to 
differentiated outcome, along with the prevalence of genetic diseases in racial and 
ethnic populations, pharmacogenomics research involving racial classification is 
anticipated to provide substantial therapeutic benefits. Such use of the notion of race 
remains controversial and contested. While CUITent genomics knowledge about 
human genetic diversity invalidates the biological basis for race as it has been 
1 The term 'genomics' is favoured over 'genetics' to denote the discipline. While the terms are used 
interchangeably, this thesis subscribes to the view that the y are to be differentiated. Genetics studies 
the transmission and expression of individual genes; genomics is concerned with the functions of the 
genes of an entire genome and the interactions between them. 
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) historically construed, researchers remain divided on the extent to which the notion 
of race can instead be rooted in social construction. Concerns surrounding the role 
of environmental factors in drug response and the poor correlation between racial 
phenotypes and genetic polymorphisms, among others, have prompted sorne authors 
to question the science behind race-based pharmacogenornics. Moreover, the very 
field of genornic science has emerged as a deterrnining influence in how individuals 
conceive difference and identity. With these considerations in mind, what ethical, 
legal, social and cultural issues are raised by pharmacogenornics research involving 
race? 
Pharmacogenornics research has implications for the protection of research 
subjects, the use and storage of genetic information and clinical practice (Nuffield, 
2003). The involvement of racial populations in pharmacogenomics research also 
raises issues that extend beyond individual harms. While constructive uses of the 
notion of race in pharmacogenornics research could bring targeted therapies to 
groups that continue to be excluded from drug discovery and development, the 
reinforcement of racial categories could lead to further stigma and discrimination 
(Smart et al., 2004; Foster et al., 1999). With the arrivaI in 2005 of BiDil, a heart 
failure drug intended for African-Americans recognized as the first racial 
prescription drug, the need to reflect on the repercussions of researching race-
specific therapeutics becomes apparent. A study on pharmacogenomics research is 
further pertinent in light of its arguably inextricable association with large-scale 
genomic databases: as biobank projects gain ground and become a platform to study 
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drug response, it will remain important to evaluate the benefits and harms within a 
broader context of population-based genomics research. A survey of the academic 
literature reveals a broad spectrum of views on the scientific legitimacy, value and 
import of using the notion of race in genomics research. But although the scholarly 
treatment has increased in recent years, there is little empirical data on the 
perceptions of genomics researchers. 
Research objectives 
The purpose of this master' s thesis is to identify the views of genomics 
researchers conceming the use of racial classification in pharmacogenomics 
research. This investigation aims to answer the following sub questions: 
• 
• 
• 
What values (moral, social, cultural) shape their perceptions? 
What do they identify as the benefits and risks for racial populations? 
What do they view as the implications of race-specific 
pharmacogenomics research for their practice? 
Because there is not much established knowledge about the views of genomics 
researchers towards the use of racial classification in pharmacogenomics research, 
the research objective is to identify and de scribe a phenomenon. This study is 
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exploratory and descriptive: the objective is to obtain information from which a 
range of explanations for the phenomenon can be extracted (Fortin, 1996). 
As recommendations derived from ethical principles bring forth new 
responsibilities for researchers and clinicians, ethical reflection would be enhanced 
with findings on how practitioners of genomic science view the use of race in 
pharmacogenomics research. Furthermore, seeking out the perceptions of 
researchers across racial populations entails taking into account the interests and 
concems of individuals likely to be impacted by the use of racial classification in 
pharmacogenomics research. The dearth of empirical data extending to the views of 
racial populations vis-à-vis race-specific genomics research reaffirms the need for an 
investigation that attaches particular importance to group benefits and harms. 
Of a qualitative research nature, this study uses the semi-directed interview 
as a data collection method. The one-on-one interview gives subjects the 
opportunity to speak, thus allowing for a better understanding of their experiences 
and the issues they encounter (Doucet, 2002). The exploratory descriptive study 
recruited genomics researchers and doctor researchers from the greater Montreal 
area who self-identified with racial populations: a total of thirteen interviews were 
conducted and analyzed. This investigation on the views of researchers on 
pharmacogenomics research involving racial classification constitutes a part of a 
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wider study into the social and ethical implications of population-based genomics 
research.2 
The first chapter of this document is devoted to a review of the literature; it 
surveys pharmacogenomics, racial science, the case of BiDil, large-scale genomic 
databases and their ensuing significance for researchers. The methodology is 
detailed in the Chapter Two while the research results are presented in Chapter 
Three. The analysis of research results and recommendations are incorporated in the 
discussion, the fourth and final chapter. 
2 "Consulting cultural communities on large-scale genomic databases: an analysis of interests and 
values". Principal investigator: Beatrice Godard, Université de Montréal. 
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LITERATURE REVIEW 
Pharmacogenomics 
As early as the 1950s, researchers have been concemed with genetics, race 
and rnetabolic differences in response to rnedication. Alving et al. observed that 
around 10% of African-Arnerican soldiers serving in World War II developed 
hernolysis after receiving the antirnalarial therapy prirnaquine, whereas only a very 
srnall nurnber of Caucasian solders fell ill (Meyer, 2004). This sensitivity was 
caused by a deficiency of erythrocyte glucose 6-phosphate dehydrogenase (G6PD), 
later found to convey a biological advantage in falôparum rnalaria-infested 
countries (McLeod & Arneyaw, 2002). More recently, it has been observed that 
sorne polyrnorphisrns found in Asian populations are responsible for poor 
rnetabolisrn of orneprazole, a drug used to treat ulcer disease (Wood, 2001); that 
rnetabolisrn of thiopurine drugs - widely used in the treatrnent of leukemia and 
autoimmune disorders - varies between African, Asian and Caucasian populations 
(McLeod & Arneyaw, 2002); and that a greater percent age of whites have irnpaired 
rnetabolisrn of the anticoagulant warfarin (Wood, 2001). 
Building on earlier studies linking race to differentiated outcorne, 
pharrnacogenornics research involving racial classification is anticipated to provide 
substantial therapeutic benefits. It proposes to identify which patient populations are 
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susceptible to respond favourably to specifie medication as weIl as which patients 
are likely to experience adverse drug reactions. The vast majority of drugs available 
on the market are believed to be effective for about 30% of patients: physicians, 
accepting this in practice, pre scribe medicines through trial and error (Roses, 2004). 
More alarmingly, it has been estimated that adverse drug reactions are the fourth 
leading cause of death in the United States, causing upwards of 106,000 deaths 
annually (Lazarou et al., 1998). Pharmacogenomics, by facilitating the identification 
of drug response profiles, would allow physicians to pre scribe in a manner that 
maximizes safety and efficacy. And given that a number of diseases have been 
associated with genetic polymorphisms more prevalent in particular populations, it 
has led many to theorize on the foreseeable development of pharmacogenomic drugs 
targeted to an individu al according to race or ethnicity. 
Indeed, the "hype" surrounding pharmacogenomics appears most fervent in 
regards to its purported integration into drug discovery and drug development 
(William-Jones & Corrigan, 2003). Possibilities include devising smaller, safer, and 
more efficient drug trials and rescuing so-called orphan drugs abandoned in earlier 
phases and targeting them to 'good responders' (Smart et al., 2004). The Food and 
Drug Administration (FDA) now welcomes submission of pharmacogenomic data 
based on "valid biomarkers" that have been rigorously tested by the scientific 
community if it explicitly affects how trials for a pharmaceutical product are 
designed (Katsnelson, 2005). 
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The science of race and genomics 
Racial diversity constitutes an increasingly appealing if not 
uncircumventable - element of pharmacogenomics research, yet a survey of the 
literature reveals that su ch a use of race is the subject of heated criticism and debate. 
When the first studies involving populations and inherited drug response were taking 
place starting in the 1950s, very little was known about the genetic basis for 
interracial differences (Kalow, 2001). It was erroneously believed that the Homo 
sapiens species could be separated into racial taxons: races were thought to be 
distinct biological species that originated independently with little or no gene flow 
between them (Witzig, 1996; Tishkoff & Kidd, 2004). As the field of genetics 
gained prominence, the discovery of overwhelming genetic similarities among 
humans led to a shift in the way researchers perceived race: the scientific community 
now widely recognizes that historical factors such as geographic isolation, 
reproductive insularity and shared lifestyle - rather than inherent taxonomical 
differences - have brought about patterns of genetic variation between populations 
(Wood, 2001; Burchard et al., 2003; Tishkoff & Kidd, 2004). 
Moreover, influential positions in the social sciences declaring race to be a 
social construction emerged decades before the findings afforded by DNA sampling 
and the Human Genome Project. In 1998, the American Anthropological 
Association updated its position: "With the vast expansion of scientific knowledge 
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10 this century, however, it has become clear that human populations are not 
unambiguous, clearly demarcated, biologically distinct groups. [ ... ] Any attempt to 
establish lines of division among biological populations is both arbitrary and 
subjective" (American Anthropological Association, 1)[ 1). The myths of race 
combine "behavior and physical features together in the public mind, impeding our 
comprehension of both biological variations and cultural behavior, implying that 
both are genetically determÎned" (ibid, 1)[ 8). The social dimension of racial 
classification has thus far been acknowledged by geneticists and genomics 
researchers, to varying degrees. 
But while the authors surveyed generally concede that race is not a purely 
biological notion, they remain divided on whether a modem understanding of race 
can be rooted in biology. This finding is echoed in the observations of sociologist 
Ann Morning (2005): 
In 2001 and 2002, 1 interviewed over 40 university professors in biology 
and anthropology about their definitions of the term "race". Their views 
varied widely. Almost 40 percent of the se academics took what can be 
called an "essentialist" view: they described races as groups of people 
who share certain innate, inherited biological traits. In contrast, over 60 
percent held a "constructionist" perspective: they argued that races do no 
correspond to patterns of human biological variation, but rather that 
racial groupings are "constructed through social processes that take 
place in particular historical, political and economic contexts. (1)[ 1) 
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Schwartz (2001) espouses the latter view when he declares race to be "a social 
construct, not a scientific classification" (p. 1392). Rejecting the biological notion of 
race, he and others have gone on to argue for the curtailment or elirnination of racial 
categories in genornics research. Confronted with growing criticism of hi~ approach, 
Francis Collins (2004) has responded: 
Well-intentioned statements over the past few years, sorne corning from 
geneticists, rnight lead one to believe there is no connection whatsoever 
between self-identified race or ethnicity and the frequency of particular 
genetic variants l • 2. Increasing scientific evidence, however, indicates 
that genetic variation can be used to make a reasonably accurate 
prediction of geographic origins of an individual, at least if that 
individual's grandparents all came from the same part of the world 3 • As 
those ancestral origins in many cases have a correlation, albeit often 
imprecise, with self-identified race or ethnicity, it is not strictly true that 
race or ethnicity has no biological connection. (p. S 13) 
Sorne geneticists and genornics researchers have taken a less comprornising stance, 
defending the biological conceptualization of race along with its clinical utility 
(Burchard et al., 2003; Risch et al., 2002). Fromwhat they de scribe as an 'objective 
and scientific' (genetic and epidemiologic) perspective, humans can be categorized 
according to the surrogate scheme of race in the absence of known, specific gene 
effects. They argue that population genetic studies have reaffirmed the definition of 
races based on continental ancestry: African, Caucasian (Europe and Middle East), 
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Asian, Pacific Islander (for example, Australian, New Guinean and Melanesian), and 
Native American (p. 3). 
Given the controversy surrounding race, the term 'ethnicity' has surfaced as 
an alternate way of characterizing differences between groups (Race, Ethnicity, and 
Genetics Working Group, 2005). Emphasizing cultural, socioeconomic, religious 
and political aspects rather than genetie ancestry, ethnicity can encompass language, 
diet, religion, dress, customs or kinship systems (ibid). However, the use of 
ethnicity in genomics research also suffers from several shortcomings. Like race, 
ethnicity is a malleable concept that implies a great degree of uniformity, leaving it 
susceptible to be misinterpreted by researchers. Individuals may identify with more 
than one ethnic group or change ethnie group altogether; ethnic groups may also 
come into existence and later dissipate according to historical or social trends (ibid). 
An emphasis on the notion of biogeographical ancestry to describe objective genetie 
relationships between individuals and among populations has in turn been suggested 
as an alternative to relying on the notion of race. (Bamshad, 2005) Citing studies of 
human genetic variation showing that genetic ancestry is highly correlated with 
geographic ancestry while only mode st correlation with race, Bamshad suggests that 
geographic ancestry and explicit genetic information appear to be more accurate 
predictors of genetic risk factors that influence health. 
Concerns surrounding the legitimacy of using race in genomics have 
prompted many authors to question the science behind race-based 
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pharmacogenomics research. Recent developments in pharmacogenomics, claim 
Rahemtulla and Bhopal (2005), renew the emphasis on biology in spite of the fact 
that historical claims of a biologieal basis to racial variation have proven to be 
overstated. Risch (2006) however argues that denying the existence or racial or 
ethnie differences in gene frequencies is unlikely to benefit minority populations. 
Furthermore, it has been argued that given the level of admixture in populations, 
extrapolating data from well-defined racial groups is scientifically problematie 
(Suarez-Kurtz, 2005). Burchard et al. (2003) take the opposite view, arguing that 
because of genetic similarities with African, European or Asian racial groups, 
persons with varying levels of admixture can be particularly useful for genetic-
epidemiologie studies. As such, the harms arising from either denying or promoting 
the notion of race remain a big concem. 
Pharmacogenomics and race: ethical issues 
With implications for the development of drugs, clinical practice and the use 
and storage of genetie information, pharmacogenomics research raises ethieal, le gal 
and social issues. As pharmacogenomics is incorporated into clinical trials, the 
protection of subjects in regards to consent, privacy and confidentiality and access to 
information has been deemed necessary to minimize harms (Nuffield Council, 2003; 
Reischl et al., 2006). In accordance with guidelines on informed consent, 
participants should be informed of the risks and able to withdraw at any time (e.g., 
Declaration of Helsinki, 'Good Clinical Practice', Tri-Council Policy Statement on 
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Ethical Conduct for Research Involving Humans). The process of obtaining consent 
would also apply to any researcher using DNA to confirm association between 
genetic variations and drug response: "testing may become an integral part of the 
methodology of clinical trials, so that taking part in a trial requires consent to 
pharmacogenetic testing"(Nuffield, 2003). Given the complex design of clinical 
trials and the volume of information, there is the risk that patients entering into 
pharmacogenomics related trials "will not have given careful consideration to all 
potential risks and benefits of this additional research" (Corrigan, 2005, p.146). 
Likewise, the breach of privacy and confidentiality emerges as an important 
issue in pharmacogenomics research. The greatest degree of anonymity for DNA 
samples (e.g. identified, coded, double-coded) should be balanced with the ability of 
researchers to fulfill the objectives of their research, thus emphasizing the need to 
weight the risks and benefits in each protocol. (Nuffield, 2003; Joly et al., 2005) As 
pharmacogenomics remains in its infancy, validated and clinically useful data for 
individuals patients may be unlikely: only in rare instances would pharmacogenomic 
analysis undertaken at various stages of research (e.g., at the enzyme level, in a 
heterogeneous patient population) yield information of immediate clinical relevance 
(Nuffield, 2003). Still, researchers could include in the consent process the 
opportunity for the research participant to receive individual feedback, if applicable. 
Communicating the nature of the genetic information and its implications thus raises 
issues of privacy and confidentiality. The increase of genetic testing that would 
accompany the integration of pharmacogenomics in clinical practice also raises 
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ethical issues such as consent in clinical practice, training of professionals in the 
administration of phannacogenomic tests, disclosure to farnily members, and use of 
genetic information by insurers (ibid). 
Pharmacogenomics research involving racial populations also raises issues 
that ex tend beyond individual hanns. Arguing for an evaluation of research that 
explores the potential group hanns, Davis (2004) argues: 
Research for persons, a pillar of research ethics, requires not only a 
respect for the individual research subject, but arguably also for the 
group whose characteristics are the object of the study. Without 
sorne measure of respect for the "group", the interests of individuals 
will not be met. Individuals have interests that the y can protect only 
through group action, and individu aIs have interests in the well-being 
of groups with which they identify. (2004, pA7) 
This evaluation is particularly relevant in light of the data showing that racial 
populations have voiced their mistrust of genomics research. As racial populations 
have been historically subjected to discrimination, stigmatization and eugenics 
attempts, many individuals are questioning their participation in scientific initiatives. 
A study by FUIT on the attitudes towards genetics research found that African-
Americans were more likely to perceive genetics as hannful to society (FUIT, 2002). 
Likewise, individuals from aboriginal populations have expressed wariness about the 
use of their DNA in research. In the past, research had been carried out without their 
consent or with the true aims of the investigators being misrepresented (Dalton, 
2002). There is concem that genomics research, by reinforcing racial categories, 
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willlead to discrimination; that members of ethnic and racial communities' access to 
the benefits of research will be restricted; and that they will lose control over how 
the y wish to define their identity (Foster et al, 1999; Weijer & Miller, 2004). 
Smart et al. (2004) con tend that the genetic stratification of patients and 
diseases characteristic of pharmacogenomics facilitates the identification and the use 
of difference. In the context of pharmacogenomics research involving race, "the 
very practice of linking [pharmacogenomics] to ethnic and racial groups should be 
recognized to have associated social risks" (p.336). Concems have been raised 
about the use of race as a proxy for genetic similarity in addition to the risk of 
viewing membership of a racial group as a substitute for a pharmacogenomic test in 
prescription decisions (Nuffield, 2003; Lee, 2003). Historical accounts suggest that 
research and clinical decisions based on racial classification have often led to poOf 
or ineffective care (Bhopal, 1998). Racial categorization in pharmacogenomics may 
reinforce race as a biological notion and undermine the rebuttals of race science 
(Lee, 2003; Rahemtulla and Bhopal, 2005; Smart et al., 2004). Moreover, entire 
racial populations could be associated with drug response, leading them to suffer 
from stigma and discrimination. Resistance to convention al drug therapy, 
emphasized in advertising for a new race-targeted drug, might convey that a 
population is biologically weaker or inferior. There is also concem that "singling 
out" a racial population might conjure up associations with differential health care 
and might promote generalization of discriminatory attitudes (Bevan et al., 2003). 
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On the positive side, the use of race in pharmacogenornics could bring 
targeted therapies to population groups that have been historically excluded from the 
drug discovery and development process (Smart et al., 2004). Failure to make 
appropriate use of difference - not using race in pharmacogenornics research to 
bene fit racial populations - would amount to an injustice. Pharmacogenornics could 
also bring savings of up to 60% in drug research and development and translate into 
a decrease in the price of drugs available to racial populations (Tollman et al, 2001) 
.This calculation was obtained through the use of a model elaborated by a 
management consulting firm which analyzed the processes involved in drug 
discovery. It remains to be seen whether pharmaceutical companies will exploit the 
notion of race in the targeting marketing of pharmacogenornic products (Lee, 2003). 
On the negative side, inequalities in drug development could lead to racial 
populations having limited access to the benefits of pharmacogenornics research. It 
has been argued that emphasis on 'good responders' in the drug discovery stage or 
during clinical trials could lead to the creation of therapeutic orphan populations 
(Roth stein & Epps, 2001). An orphan drug refers to a treatment for a rare disease 
affecting relatively few people: the U.S. Orphan Drug Act puts this number at 200 
000 people or altematively, for a disease affecting more than 200 000 "for which 
there is no reasonable expectation that the cost of developing and making available 
in the United States a drug for such disease or condition will recovered from sales in 
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the United States of such drug" (Orphan Drug Act, SEC. 526 [360bb], (2), 1983). 
Rothstein and Epps argue that similar therapeutic orphans could emerge as 
pharmacogenomic frames lower prevalence in terms of drug response rather than 
disease and facilitates the identification of populations that do not respond to drugs 
in research trials. There is concern that orphan populations may come to reflect 
existing patterns of inequality: pharmaceutical companies may face a financial 
disincentive in developing products for socially marginalized minority groups 
(Smart et al., 2004). Several authors anticipate that eventual pharmacogenomic 
drugs will be expensive, therefore making them inaccessible to already marginalized 
and impoverished populations (Roth stein & Epps, 2001; Smart et al., 2004). 
There may be further implications for existing health disparities between 
racial populations. The use of racial categorization in pharmacogenomics occurs in 
a broader social context of discrimination and inequality based on racism (ibid). Lee 
(2003) cautions that the emphasis on genetics in drug response may undermine other 
explanatory mechanisms such as the features of the social and poli tic al environment 
that lead to ill health. Decisions about resource allocation and priority setting in 
research raise issues of justice: funding pharmacogenomics research may move 
spending away from studying and tackling known socioeconomic determinants of 
health (e.g. access to health care, diet, housing) and could in turn exacerbate 
inequalities between racial populations. In a context of limited funds for research, 
the emergence of public health genomics along with the calI by sorne researchers for 
increased research into how best integrate pharmacogenomics into regular care has 
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others asserting that public health ethics would argue against the use of public funds 
to provide genomic technologies that have not been appropriately evaluated 
(Thomas et al., 2005). In regards to distributive justice, the Declaration of Helsinki 
requires that populations benefit from research and that the risks and benefits of 
research are distributed fairly to both individu al participants and to the communities 
to which the y belong (World Medical Association, 2000). This could involve 
inclusion in research trials, drug subsidies, access to alternative treatment, and 
investment in future research, thus accounting for both the short and long-term. The 
tension between inclusion in research and exclusivity for racial populations 
complicates the assessment of pharmacogenomics research' s impact on social justice 
(Lee, 2003). 
The case of BiDil 
The approval of BiDil as the first racial prescription drug in 2005 provoked a 
debate on the implications of race-based therapeutics, causing ethicists, researchers 
and clinicians to question the pervasiveness of race in biomedical research (Bloche, 
2004; Kahn, 2004; Rahemtulla and Bhopal, 2005; Duster, 2005). Their analysis of 
the study design, commercialization, marketing and public response can thus serve 
to enrich the ethical reflection on the use of racial categorization In 
pharmacogenomics. More importantly, the BiDil case continues to provide an 
example of what future pharmacogenomics research involving race may entail. 
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Numerous studies suggest that African Americans suffer heart failure and die 
from heart failure at a disproportionate rate when compared to other populations. 
Citing this research, and building on the investigators' observations that the BiDil 
combination of isosorbide dinitrate (a blood-pressure drug) and hydralazine (a chest 
pain medication) had benefited the black subjects in previous studies despite not 
receiving FDA approval due to scant conclusive evidence, Nitromed Inc. initiated 
the African-American Heart Failure trial to determine BiDil's efficacy (Kahn, 2004). 
Clinical findings from A-HeFT indicated that BiDil reduced death rates at a rate of 
43% (Nitromed Inc., 2004). Vpon its release, BiDil was heralded by many 
prominent physicians including Malcolm Taylor, Chair of the Association of Black 
Cardiologists who co-sponsored A-HeFT, as a landmark for the treatment of African 
Americans and "a significant step forward in addressing [health] disparities 
(Vardese, 2005). 
The investigators' claim of a different pathophysiology for African 
Americans necessitating different treatment remains controversial. Several authors 
have noted that testing BiDil exclusively on African American patients does not 
demonstrate greater efficacy for African Americans than for other groups (Lee, 
2003; Kahn, 2004; Bloche, 2004). The trial investigators themselves concede that 
BiDil will work in people regardless of race (Kahn, 2005). Genetic variability 
within racial groups would also mean that BiDil may not necessarily work for all 
African American individuals (Balakrishnan, 2004). "The only responsible claim 
that can be made on the basis of the se trials", writes Kahn (2005), "is that BiDil 
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works in sorne people who have heart failure - period." There is also the concem 
that health care providers will not prescribe BiDil to other populations while 
in surance carriers may be reticent to reimburse such off-label uses (ibid). Further 
considerations to justice are raised in light of the daim that Nitromed is profiting 
from merely combining two drugs available separately in generic formulations at an 
approximate cost of 44 cents per dose (Bloche, 2004). Nitromed's second BiDil 
patent for use in African Americans (the first ever granted for race-specific use) 
effectively pushes back market entry for generics to 2020 (ibid). Nitromed has since 
introduced a program to subsidize the cost of BiDil for low-income patients 
(Nitromed Inc., 2005). 
Kahn goes on to argue that marketing a race-specific drug such as disease 
can lead to a mis allocation of health care resources; it can also contribute to the 
perception that health disparities are caused by an absence of "Black" drugs rather 
than an array of environmental, social and economic factors as weIl as the 
discrimination African Americans experience in the D.S. health care system (2005). 
Although BiDil is not a product of pharmacogenomics research, it appropriates 
notions of genetics by suggesting innate causes for drug response in patients who 
self-identified as Black (Bloche, 2004). Other pharmaceutical companies may stand 
to gain from using the notion of race without fully appreciating the ethical 
implications. 
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Large-scale genomic databases 
The ethical, social, legal and cultural issues surrounding the participation of 
racial groups in pharrnacogenomics research are further complicated by the 
prominent role that will play large-sc ale genomic databases. Although the y appear 
to usher in an era of 'personalized medicine', advances in pharrnacogenomics 
research remain unattainable without population-based approaches. Indeed, "in the 
absence of cost-effective, ubiquitous genome scanning tests, it may be more accurate 
to describe the next wave of genomic medicine as population-based rather than one 
focused on individual differences" (Lee, 2003). 
A large-scale genomic database (or biobank) contains biological samples as 
weIl as personal information of a genetic, medical, genealogical and sociological 
nature. Focusing on a population, it aims to identify genetic characteristics of an 
entire society (Commission de l'éthique de la science et de la technologie, 2004). 
Large groups of selected individuals are asked to volunteer DNA samples for genetic 
analysis and to fill out questionnaires. The CART@GENE project will recruit 60 
000 adult volunteers in Quebec whereas the Icelandic Health Sector Database, UK 
biobank and the Estonian Genome Project have set recruitment targets of 270 000, 
500 000 and 1 605 000 samples respectively (RMGA, 2005; Cambon-Thomsen, 
2004). 
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By their scale, format and scope, genomic databases represent "a novel, high-
risk initiative that has the potential to pro duce breakthroughs in genomics" of 
clinical usefulness (Guttmacher & Collins, 2002). But as the organizers of large-
scale genomic databases have proposed a recruitment unbiased with regards to 
disease or race yet at the sarne time representative of population density, there has 
been growing concern sUITounding the ethical implications of biobanks for racial 
populations (Godard et al., 2004; Joly & Knoppers, 2006). In 2003, Howard 
University announced plans to build the first 'racial' population DNA database from 
sarnples obtained from African-Americans (Cambon-Thomsen, 2004). Large-scale 
genomic databases rai se issues about human identity, protection of personal data as 
well as fears of stigmatization and discrimination (Godard et al., 2007). Once the 
research results of such initiatives are made public, individuals of a certain age or of 
a certain lifestyle could become associated with diseases of a genetic nature; 
similarly, a person could be viewed as susceptible to disease simply because of his 
place of residence or birth. There is also the risk that stored data could be used for 
ends other than the proposed research (e.g. genetic information divulged to 
government authorities or employers) (ibid). 
Implications for researchers 
The use of racial classification in genomics and pharmacogenomics research 
holds far-reaching implications for researchers. Recommendations such as the 
creation of incentives to develop new drugs for subpopulations, tighter monitoring of 
22 
pharmacogenomics trials, improved controls on genetic testing and data, and anti-
discrimination measures necessarily bring forth new responsibilities for researchers 
and clinicians (Smart et al., 2005). Lee contends that sorne researchers view their 
work on human genetic variation as untainted by social ide as and values; 
consequently, the y feel little pressure to be explicit about the meaning and 
significance of race in framing their research hypotheses (2005). Investigators that 
identify and use racial distinctions, in addition to having a clearly defined and 
testable hypothesis, should provide a scientifically valid definition of the population 
under study (Schwartz, 2001). Moreover, studies involving genomics and self-
identified race should be rigorous, well designed, large-scale and long-term, as well 
as undertaken in multiple populations (Collins, 2004). 
Pharmacogenomics research involving race also provides a new context for 
understanding the duties of researchers as outlined in normative texts. Principlism 
has emerged as the predominant normative framework in genomics research. The 
fundamental bioethical principles of respect for the individu al, beneficence, non-
maleficence and justice have been recognized in statements of principles on genetics 
research issued by the United Nations Educational Scientific and Cultural 
Organisation's International Bioethics Committee (UNESCO, 1995), the Human 
Genome Organization (HUGO, 1996), the World Health Organisation (WHO, 1997) 
and Quebec's Réseau de Médecine Génétique Appliquée (RMGA, 2003). An 
analysis of the benefits and risks of the use of race in pharmacogenomics research 
entails identifying how these ethical principles may be fostered or threatened. 
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Seeking out the perceptions of researchers can provide insight into how ethical 
principles - and the research recommendations from which they are derived - are 
interpreted and experienced by genomics researchers. The principle of respect for 
communities figures prominently in both normative texts and the surveyed ELSI 
literature. Weijer et al. suggest that it "confers on the researcher an obligation to 
respect the values and interests of the community in research and, wherever possible, 
to protect the community from harm" (Weijer et al., 1999, p.275). The use of race in 
pharmacogenomics research thus has implications for researchers that involve 
thinking of group and community harms associated with the use of race. 
Several authors calling for a "greater institutional oversight of race-based 
scientific daims" (Lee, 2005) in pharmacogenomics, however, argue that it should 
ex tend beyond proposed study protocols and also involve an assessment of how the 
very notion of race is used in the scientific community. Misleading or 
counterproductive uses by researchers must be remedied (Collins, 2004). Schwartz 
suggests that from the very beginning, instruction in medical genetics should 
emphasize the fallacy of race as a scientific concept. Researchers, maintain Sankar 
et al. (2004), should not overstate the role of genetics in explaining health disparities 
between racial populations; the y should remain focused on addressing the known 
social causes (Fine, 2005). Rather than rely on race as proxies or flawed surrogates, 
genomics researchers should be required to pursue additional research to explicate 
underlying mechanisms (Lee, 2005). Above aIl, professionals dealing with 
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pharmacogenomics re~earch results involving race need to take an open minded but 
critical stance (Rahemtulla and Bhopal, 2005). 
Although there have been a growing number of articles contributing to the 
scholarly treatment of pharmacogenomics and race, little empirical research has 
been done into how the practitioners of genomic science perceive theses ethical 
concems, or into how they view their own roles in pharmacogenomics research 
in volve racial classification. At least three studies have investigated the attitudes of 
lay people towards race-based therapeutics. In a study on direct-to-consumer 
marketing, Bates et al. conducted focus groups to examine the reaction of 
participants to advertisements for a fiction al race-based medication (2004). While 
the participants resisted the message that African Americans are different from other 
races and may need a particular medication for a common disease, there were 
differences of interpretations along self-identified racial lines: African-Americans 
were more likely to fear racial discrimination and a substantial minority believed 
such a drug indicated a changing medical environment. Bevan et al. found that 
participants, suspicious of race-based prescription, preferred individual genetic 
testing as an option for prescription because it provided individualized attention 
(2003). The results of a telephone survey on the attitudes of individuals towards 
pharmacogenomics highlight interest in pharmacogenomic research and willingness 
to participate in it, but also continued concems over who gets access to genetic data 
(Roth stein & Homung, 2003). 
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Meanwhile, no similar studies have been conducted with respect to the views 
and attitudes of professionals. A review of the literature has not uncovered any 
study on the perceptions of researchers towards the use of racial classification in 
genomics or in biomedical science. Several empirical studies have been undertaken 
in regards to the perceptions of genomics researchers spanning a myriad of issues 
including genetic engineering (Rabino, 1991), comparisons between European and 
American researchers (Rabino, 1994), commercialization (Rabino, 1998; 2001), data 
withholding (Blumenthal, 1996), and science policy (Matthews et al., 2005)3. In 
Quebec, a recent study consisted of interviews with genomics researchers with the 
aim of identifying their professional responsibilities (Boutin-Ganache, 2006). 
Although an increasing number of commentaries and opinion pieces written by 
researchers on pharmacogenomics research involving race are being published in 
academic joumals, the dearth of empirical data reaffirms the relevance of the present 
study. 
3 These references were obtained from a literature review compiled by Isabelle Boutin-Ganache for 
her doctoral dissertation Recherche en santé humaine, génétique et génomique au Québec - Les 
normativités implicites de la communauté scientifique et l'élargissement de l'éthique au Québéc 
(2006). 
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METHODOLOGY 
Data collection 
This investigation on the views of researchers on pharrnacogenornics 
research involving racial classification constituted a part of a wider study. 
"Consulting cultural communities on large-scale genomic databases: an analysis of 
interests and values", for which Beatrice Godard is the principal investigator, was a 
study into the social and ethical implications of population-specific genornics 
research. Large-scale genornic databases would enable to researchers to uncover the 
breadth of genetic diversity and the extent of genetic sirnilarity within populations, 
including racially identified ones. They would sirnilarly prove to be indispensable to 
future pharrnacogenornics research as the data collected in biobanks would serve as 
a platform to study drug response. Interviews that incorporate views on large-scale 
genomic databases and human genetic variation thus provided a fitting context for 
understanding the implications of pharrnacogenornic research involving race. 
Godard et al.'s exploratory descriptive study among insiders and outsiders 
sought to interview researchers, clinicians, political leaders and spiritual leaders 
from ni ne populations in the greater Montreal area: 1) Aboriginal; 2) Chinese; 3) 
Greek; 4) Haitian; 5) Hispanic-Canadian; 6) Indo-Pakistani; 7) Italian; 8) Jewish and 
9) Moroccan. The selection of populations, which reflect sorne of the racial 
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categories often used in biomedical research, has been do ne according to the 
ethnocultural portrait from the 2001 census by Statistics Canada. Since sorne 
diseases occur more frequent - though not exclusively - in a defined population, 
such as Tay-Sachs in Jewish Ashkenazi, thalassemia in Italian and Greek, and sickle 
cell anemia in Haitian, members of the se populations were deemed likely to be 
solicited and involved in genomic databases projects. The Master's study is situated 
in the broader research project as having a specific focus on the ethical issues 
sUITounding pharmacogenornics research and race. The overlaps are the data 
collection instrument and the data sample, with the genomics researchers 
interviewed for this Master' s study part of the larger sample. The data pertaining to 
the political leaders and spiritual leaders is not subjected to treatment in this work. 
The research findings from Godard et al.'s study, which differ from those of this 
thesis, are also not presented here. 
This Master' s study' s contribution to the larger study design was the 
inclusion of questions pertaining to pharmacogenornics. The interview guide 
touched upon large-scale genornic databases, genomics research, pharmacogenornics 
research and community concems. It was designed to favour an exchange with the 
interviewer about issues and perceptions identified by doc tors and researchers in 
genetics or genomics, anticipated to have insight into the selected populations, and 
engage them in a discussion of how they perceive their role in the scientific 
discourse sUITounding research, difference and identity. The types of questions 
ranged from questions about the researchers' perceptions, with an emphasis on their 
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personal experiences (Est-ce que vous participeriez à un projet de biobanque si 
l'information recueillie servait à la recherche et au développement de 
médicaments?; Croyez-vous qu'un tel produit pharmacogénomique aura des aspects 
positifs/négatifs (sociaux et médicaux) sur votre communauté?) to questions 
incorporating noteworthy cases (the HapMap project, BiDil, the breast cancer drug 
Herceptin) (See Appendices under «Research Questionnaire »). The study protocol 
and consent form were reviewed and approved by the research ethics cornrnittee of 
the Faculty of Medicine of the University of Montreal. 
Genomic scientists from academic or institutional research centers, doctor 
researchers and clinicians were recruited for in-depth, semi-structured interviews. 
The recruitment of respondents was done in collaboration with two partners, l' 
Institut Interculturel de Montréal and Direction de Santé Publique de Montréal. 
Having gained a wide experience in ethnocultural and intercultural investigation, 
their understanding of the realities of specifie groups, communities and the nature of 
their interactions enabled the identification of key organizations and informants. A 
snowball recruitment technique was employed. After e-mail and telephone contact 
requesting participation was established, study staff responded to questions and 
scheduled the interview with interested individuals. Study respondents later referred 
the investigators to potential participants. Participants were not compensated for 
agreeing to take part in the study. 
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Godard et al.'s qualitative study involved a nonprobablistic, purposive sample of 24 
interviews. Specifically, a random sample was interviewed with a view to 
identifying prevailing attitudes. The size of the sample was established inductively 
and sampling was continued until data saturation occurred, i.e. until the point in data 
collection when new information produced little or no change, to get a reliable sense 
of thematic exhaustion and variability within our data set (Gue st et al., 2006). Data 
saturation was achieved after interviews with 13 researchers (9 laboratory 
researchers and 4 clinician researchers). Thirteen interviews is the sample size for 
this thesis project. The researchers were representative of the following populations: 
Aboriginal, Chinese, Greek, Haitian, Hispanic-Canadian, Indo-Pakistani (2), Italian, 
Jewish, and Moroccan. While the researchers were of different racial categories, 
the y were selected on the basis of identification with the populations identified for 
Godard et al.'s study. Of the nine laboratory researchers, one's work consisted of 
work in pharmacogenomics while the rest worked in genomics (molecular 
Immunology (2), pediatrics, cardiac diseases (2), reproduction, neuroscience, and 
oncology). The clinician researchers were from the fields of reproduction (2), 
pediatrics and psychiatry. 
Data analysis 
The interviews were digitally recorded and transcribed. The digital audio 
files of the interviews were later destroyed. A thematic analysis of interview 
transcripts was undertaken following recognized academic and ethical standards for 
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qualitative research, to ensure the quality and validity of findings and the protection 
of research participants (Mays & Pope, 1995; Malterud, 2001). This qualitative 
method serves to extract consistent themes. Themes from respondents' accounts are 
identified by bringing together components of fragments of ideas or complete ideas, 
which often fail to convey meaning when viewed in isolation. .At the end of the 
analysis, themes that emerge from the respondents' accounts are pieced together to 
form a comprehensive picture of their collective experience. This process allows us 
to identify, compare and contrast the interests, values and concerns of each 
respondent and rank them according to their subjective importance (Graves et al., 
1998; Kletter et al., 1998). 
The analysis of the data collected for the study "Consulting cultural 
communities on large-scale genornic databases: an analysis of interests and values" 
was performed using the pro gram Atlas.ti. For the purpose of this Master' s project 
on the researchers' attitudes towards pharmacogenomics research involving race, the 
data was analyzed without the use of Atlas.ti software. 1 proceeded to do a thematic 
analysis adopting the framework for qualitative data analysis developed by Miles 
and Huberman (1994). Throughout the course of the analysis, 1 sought to identify 
patterns and common themes; atypical responses and deviations from the se patterns; 
and interesting facts emerging from the interview transcripts. 
The thirteen interview transcripts were read in their en tiret y to ensure 
farniliarity with the data. The data was then condensed and made manageable by 
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retaining the passages that were of relevance to the research questions and setting 
aside the data that weren't. Data reduction refers to the process of selecting, 
focusing, simplifying, abstracting, and transforrning the data that makes up the 
transcribed material (Miles & Huberman, 1994). This process of reduction was first 
informed by the research questions, with the material deemed redundant being 
extraneous or tangential. For instance, anecdotes - albeit interesting ones - that 
veered off-topic were excluded from the coding process. The data was preserved in 
its original format as thirteen documents in interview questions and answers. For 
example, mentions of particular diseases were identified separately: diabetes (Code: 
mal.dia),. thalassernia (Code: mal.thala), sickle ceIl anemia (Code: mal.anem), etc. 
They came to be grouped under a metacode category of citations dealing with the 
health of populations and communities (Metacode: SANTE), which included codes 
on distinctive initiatives related to health along with their perceived impacts (see 
Appendices under "CODES"). 
Afterwards, the data was subjected to coding. A fundamental part of data 
reduction, coding involves naming, classifying and noting regularities in the material 
(Miles & Huberman, 1994). The unit of analysis chosen for the coding was the 
sentence. A prelirninary analysis of the interview questionnaire and the theoretical 
framework was used to identify theme categories. During further readings of the 
interview data, codes belonging to the theme categories as weIl as addition al ones 
were used to inform the coding process. Afterwards, the codes were refined as more 
data were analyzed; metacodes denoting themes were added. 
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An organized assembly of information that permits conclusion drawing and 
data display provides a new way of arranging and thinking about the data (Miles & 
Huberman, 1994). The coding being done manually, the data display was done in 
text form: for each respondent were listed the categories that emerged during the 
coding process. A 'within-case' or 'vertical' method of analysis was used: each 
interview was analysed individually in order to extract a profile or general portrait of 
the subject. Thereafter, the attitudes and views attributed to each subject were 
compared to those of the other study participants. This was favoured over 'cross-
case' analysis, in which the interview text is broken down by subject to reveal 
relations between variables, because as an inductive method it is best suited to an 
exploratory study. 
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RESULTS 
The interviews uncovered a richness of views and attitudes among genomics 
researchers. The topics discussed during the interviews included: the impact of 
large-sc ale genomic databases for pharmacogenomics research, DNA sampling and 
storage, genetic diseases, commercialization, intellectual property, genetics research 
in developing countries, attitudes towards genetics research, spiritual values and 
genetics, and historieal scientific theories on race. The central themes that emerged 
are the following: the scientifie study of differenee; the benefits for 
pharmacogenomies researeh; the repereussions of undertaking race-specifie 
research, the use of information; and the need for ethical oversight. These themes 
will be elaborated below. 
Interest in studying difference 
The researehers shared the perception that scientifie investigation involving 
genomics and racial classification eould best be understood as a study into 
difference. The science of genomies, they emphasized, focuses on inherent 
biological differences. While sensitized to the negative connotations of researeh 
involving race, they said they were very interested in the study of diversity; they did 
not feel that the "stigma" or "taboo" should constitute an obstacle to furthering 
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scientific knowledge. The researchers perceived their interest into race and 
genomics to be motivated by intellectual curiosity. 
When asked to elaborate on this self-proclaimed "need to know", the 
participants delved into scientific explanations: differences between races exist at the 
genetic level, and the se in tum justify the need for pharmacogenomics research 
involving racial classification. They conceded that humans share the same genetic 
code but that variations differ in frequency between Black populations (the intended 
consumers of BiDil) and other populations. The researchers went on to explain that 
given the occurrence of genetic variations between populations, separating study 
subjects along racial lines allowed for greater accuracy in genomics studies. At the 
same time however, several respondents noted that the level of genetic variation was 
"minimal" . 
"There's just a whole range of variation. It's not just a set of genes for 
Black people: it's a whole range of variation and a lot of those genes are 
shared between races. The number of genes that actually cause races to 
look different is very small. Most of the genes are very, very similar; 
it's just a few genes that cause the differences." 
Three of the researchers opted to draw a distinction between the biological and 
social connotations of race. Emphasizing the importance of relying on genetic 
makeup in biomedical research, one of them commented: 
"There are two aspects: the social and the genetic. The social 
connotation that is pervasive is based on your skin colour, where you 
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come from, where your parents come from: that's completely different 
than your genetie makeup, than your race, where your ancestors came 
from. The bloodline, the lineage. 1 think that's two different topies and 
1 think it's important to keep them separate." 
They acknowledged that this interplay between biological and social notions renders 
it more difficult to clearly delineate between populations. According to another 
respondent, admixture between so-called racial populations adds to the complexity 
of studying difference. 
"Races are so mixed that it's hard to subscribe to this [notion of race]. 
We already have to deal with mixed, intermixed populations for whieh 
we can no longer apply anything. If we talk of the skin colour of a 
Black person as being dominant while the other colour is a recessive 
trait, and if in that case someone is of lighter skin colour ... are we really 
dealing with a Black population?" 
The researchers felt very strongly that research into the genetic differences 
between racial groups needed to be scientifically legitimate. And though they 
described the field of genomics as evolving rapidly and urged more research, the y 
did not call into question the legitimacy of earlier studies - predating the Human 
Genome Project - linking race with inherent biological difference. They said the y 
were motivated to undertake studies involving racial groups because these reflect the 
diversity of Quebec's and Canada's society. Indeed, the researchers said they were 
encouraged by the rise of studies aimed at discovering the genetic particularities of 
populations long ignored by the research establishment. 
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"Scientists primarily want to know. They are concemed with finding 
knowledge. Of course, being such a diverse community of genomics 
researchers means that people are more aware of the kind of uses. If you 
go to any lab today, you will find people from aIl over the world, a real 
United Nations! That's why it would be difficult to imagine a researcher 
wanting to purposefully harm someone who is in the same research unit, 
or in the same building. Researchers ultimately want to do good. They 
want to use genetic information from populations to help cure or prevent 
diseases. " 
Enthusiasm for the benefits 
Almost aIl the researchers said they were very enthusiastic about CUITent 
pharmacogenomics research and its future implications for both genomics research 
into disease and drug development. They were adamant: pharmacogenomics 
research involving race will lead to better health-care outcomes. The respondents, 
discussing the potential benefits, elaborated on differential drug response and 
prescription decisions by physicians. 
"The way 1 see it, it's a good thing because if there is a variation in the 
genome associated with drug response and this variation occurs more 
frequently among Europeans, for example, we give a bigger or smaIler 
dose according to response. It's going to amount to a more effective 
treatment." 
"Before, with people suffering from diseases, doctors came in and gave 
everybody the same medicine. [ ... ] If we have such information, ifl get 
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sick and go see the doctor, 1 have the information on which medication 
for me is best and which is of no use. 1 can get a quicker and better 
treatment." 
"There hasn't been enough breakdown into looking at specificity: we are 
all different. As 1 said, our lineage cornes from different places and 
along the travels of the se lineages, mutations have occurred. That 
maybe makes us better drug metabolizers or worse drug metabolizers. 1 
don't think there has been enough study to deterrnine how we can 
benefit from knowing the differences according to race." 
The benefits for racial populations, they anticipated, would be substantial. In 
addition to benefiting from a more specialized administration of currently prescribed 
drugs, individuals could have access to targeted drug interventions for the rare 
diseases more prevalent in racial populations. One researcher - perhaps wary of 
unfettered enthusiasm - emphasized the need for a serious commitment to research: 
"We've often seen scientists get enthusiastic about new technologies 
without them having the expected results or applications. Especially 
considering that there will be important social impacts. [ ... ] Right now, 
pharmacogenetics, pharmacogenomics is considered "hot". My 
perception is that before we can say that su ch outcomes will happen, 
there needs to be more research. " 
The case of BiDil provided the respondents with the opportunity to weigh in 
on the benefits of having a race-specific prescription drug available on the m~ket. 
They generally shared the opinion that a heart failure drug that could improve the 
health of African-Americans was a "good thing" and a significant step towards 
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personalized medicine. However, they did not foresee that pharmacogenomics 
research involving race would bring about pharmaceutical products resembling 
BiDil but rather modifications in prescription and dosage, and the development of 
new therapies made possible through the identification of specifie genes. In their 
understanding, these benefits would invariably be spread out among all racial 
populations. A majority of the respondents were surprised to learn that BiDil was 
only intended for Black patients. 
"rd be surprised if only African-Americans can take it. There's no dear 
dividing line in genetics, a lot of diseases are shared between races. 
African-Americans rnight be more subjected to certain things but it's not 
0% for White people. There are also a percentage of them that will be 
susceptible to it so this drug is probably good· for non African-
Americans or African-Canadians." 
One researcher, perplexed by the scientific daims behind BiDil, expressed the 
following thought: 
"It's worrying that race and drug are conflated in this way. If there are 
drugs based on a misconception, ultimately, we won't see an effect. 
These days, patents are huge business. That's not productive science. 
They, the companies, go for business. If they want to sell a drug for two 
years, they don't care it's pulled off: the y made their money. 1 hope it's 
not hurting people." 
In contrast, another researcher offered a more positive view: 
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"1 think that if it had the approval of the FDA, it means that it is resting 
on solid scientific data. Meaning that effectively, if we administer this 
drug to African-Americans, we know that it works and that it works 
better than other things. In this light, this does not pose a problem." 
Above aIl, the researchers' main preoccupation with a race-specifie drug remained 
the existence of tangible therapeutic benefits. Pharmaceutical products derived from 
pharmacogenomics research, with their many foreseeable advantages, would in their 
view eliminate the need for drugs developed in the manner of BiDil. 
Concerns for potential harms 
A major concem for the respondents was the potential misuse of research 
results by in surance companies, employers and govemments. It was feared that 
linking a population with the need for a particular drug could lead to instances of 
institution al stigmatisation and discrimination. 
"Canada is a country of immigrants. [ ... ] Let's suppose that tomOITOW 
we discover that the Haitian population has a genetic profile. 'We are 
uneasy because in terms of health and our overburdened health care 
system, they will develop medical problems. We will likely recruit 
immigrants from populations that are genetically 'unsoiled". These 
are the kinds of deviations. How will this information be used?" 
Concems also arose over the use of the personal information of the individuals who 
would contribute DNA used in pharmacogenomics studies, as well as of those 
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participating in drug trials. One respondent surmised those risks could discourage 
individuals from participating in genomics research. 
The researchers felt that financial incentives for the pharmaceutical industry, 
which they portrayed as being motivated first and foremost by profits and ils 
financial bottom Hne, would emerge as the deciding factor in the research and 
development of pharmacogenomics. While sorne decried this business model, others 
reasoned that the industry' s concern with financial return was justified seeing as 
drug development was lengthy, risky, complex and prohibitively expensive. 
Companies were not perceived as being willing to invest in drugs intended for racial 
populations if the market for a drug was too small given a population's purchasing 
power or the rarity of a medical condition. This presented an ethical dilemma for the 
respondents; this scenario conflicted with their belief that research should not 
penalize or exclude individuals because of race or socio-economic status. 
Governments and charitable foundations were cited as alternative sources of 
pharmacogenomics research funding. 
In addition to the absence of financial incentives, the researchers 
acknowledged that racial inequality could lead to Black patients being deprived of 
the benefits of pharmacogenomics. For at least two researchers, racial stratification 
for the purposes of drug development evoked memories of past injustices, such as 
the Tuskegee study and the export of drugs with dangerous side effects to 
developing countries. 
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"That's the kind of suspicion 1 would have towards a drug destined 
exc1usively for a minority who se economic power is fairly weak. 1 
wonder .,. not necessarily if this drug is beneficial but rather has 
testing been done? Are they going to put in the same energy and do 
the tests with the same rigor to ensure the identification of side effects, 
in the long term just like with a drug destined for sale on a wider 
scaleT 
They expressed concems that Black patients could become guinea pigs and receive 
unrefined treatments before they are improved and made available to White patients. 
Furthermore, preoccupations arose surrounding the Quebec govemment's 
willingness to subsidize the cost of drugs destined for minority populations through 
its drug insurance scheme. Sorne wondered whether political decisions on drug 
reimbursements would be made at the expense of the health of Black individuals or 
others. The respondents were united in their beHef that the more specialized 
treatments made possible by pharmacogenomics would constitute a challenge to 
Quebec' s attempts at a universal health care system. 
A wareness of the implications of research involving race 
The researchers acknowledged that although much remains to be discovered 
in pharmacogenomics and differentiated drug response between racial groups, 
racism is an undeniable reality. By far the most worrying repercussion of tbis 
42 
research, in their view, is that it could be used to rationalize racism. In spite of the 
ambiguity and confusion sUITounding the scientific study of race, research results 
could be used to support genetic reductionism, i.e. the definition of individuals' 
identities based on their DNA. 
"1 study evolution, 1 study genetics, how things change through time, 
why sorne things go this way versus that way in different parts of the 
world. So 1 think it's really interesting. Yet, a person who is interested 
in other things can just take that information and say, "Now we know 
what constitutes a pure Han Chinese or whatever". For me, that's the 
dangerous part." 
The respondents were concemed that researchers with racist views could manipulate 
their study designs or research results. One researcher spoke of the strong 
convictions that drive researchers while another cautioned about the far reach of 
conclusions drawn from race-related research. 
"1 think researchers are driven by their own needs. They get this idea in 
their head, they get this bee in their bonnet and the y just have to do it. 
Now, 1 think most researchers have actually quite pure motives but 1 
think sorne are subverted. Remember, the worst racists in the world 
have been doctors. Raskovic, the Serbian leader who was into ethnie 
cleansing: he's a psychiatrist." 
"Suppose 1 have an a priori that Blacks are intellectually inferior. And 
that in the research uncovers differences in the genome. [ ... ] A link is 
going to be established ... do you see the deviations in this case? That's 
why, in my opinion, this has to be handled with a humanist and human 
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approach. Comprehensively. We have to be extremely careful as soon 
as subdivided people into ethnie subgroups or genetic subgroups. We 
have to be careful of that and also of how it' s going to be used. Human 
beings are not solely a genetic code. They also are a wide number of 
things we can objectivate." 
The respondents had very strong misgivings about research linking genes and 
intelligence. They felt that using racial data in the discovery of medical treatments 
was invaluable whereas investigations linking race with behavioural and other traits 
were not warranted - and in sorne instances even morally reprehensible. 
The legitimization of genetic reductionism also proved to be of interest to the 
respondents because of its implications for the understanding of disease. One 
respondent spoke of the implications of the genetic paradigm: 
"It brings us to reflect on our very conception of medicine and care. 
80% of the world's population is far from thinking of genetics: that is 
the conception coming from the West. This brings up ethical questions. 
Chinese medicine, whieh is 5000 years old to Western medicine's 2000 
years, has clearly different approaches. Is genetics going to overthrow 
all of that? In Africa, there are particular aetiologies that take into 
account traditions and the treatments reflect that. We have to take this 
into account. Or are we doing research for care destined exclusively for 
the West, are we heading towards this alone?" 
They emphasized that genomics research was increasingly devoted to the study of 
multi-factorial diseases such as diabetes, heart disease and cancer: it would be wrong 
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to suggest that the incidence of disease in racial populations is essentially tied to 
genes. 
"There is complexity of the human organism; the complexity of disease; 
the complexity of genes. When we speak of a disease, it involves 
susceptibility, infection, environ ment , poverty ... there are multiple 
factors. It's not simple." 
The respondents stressed the need for greater collaboration between genornics 
researchers and other scientists. This would benefit research by improving the 
understanding of the gene-environ ment interactions. Researchers from disciplines 
other than the biological sciences were sirnilarly deemed crucial to the 
understanding of the social deterrnÏnants of health. 
Respondents spoke at length about the challenges of disserninating research 
results to the general public. Without a firm grasp of the science behind genornics, 
individuals are likely to infer genetic reductionism and rnisunderstand the notion of 
genetic risk. When asked if their perceptions rnight differ from those of individuals 
in their community or in their general public, they believed their work as scientists 
made them see the issues differently: 
"1 think l'm probably in the rninority in that l'm Greek but also a 
geneticist, a scientist. 1 have a unique perspective that most of Greeks in 
the community don't have because 1 study this for a living. 1 think my 
views probably wouldn't be shared by the majority of Greeks." 
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"If you have a good ex ample and can explain weIl, most Chinese people 
will be interested in the research. Now, l'm a researcher, l'm a scientist: 
1 understand what you do and the importance but not like usual people. 
The people working in a bank or in a restaurant may not have this basic 
knowledge. If Chinese people could explain in the local language, that 
would be great." 
They felt that the level of misinformation surrounding genomics and race is 
alarming: consequently, the public may misinterpret research resuIts. Public 
understanding of pharmacogenomics research involving race thus stood out as a 
priority for the respondents. Among the methods suggested: developing scientific 
literacy at an early age, popularization in the media (television, newspapers, radio, 
internet), public debates, etc. Almost all the respondents commented that scientific 
terms would need to be made c1earer, abstract concepts made more accessible. One 
respondent singled out politicians as having influence on the public and needing to 
be educated. For the most part, the researchers believed that a better understanding 
of genomics would lead to greater public acceptance of their research. Still, 
researchers saw their role in this process as limited. They saw themselves as being 
responsible for providing raw scientific data. 
Need for ethical oversight 
The respondents spoke of the importance of ethics in regulating 
pharmacogenomics research involving race. In their view, reflection on ethical 
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issues by genomics researchers was generally seen as something exterior to the 
practice of research. 
"Yes, many see that as one administrative step that has to be done in 
order to do the research. That' s unfortunate, there' s not that concem for 
the repercussions of the research." 
In the words of one doctor researcher: 
"Right, it's like every doctor-patient encounter that you have is an ethics 
consult. There's always ethics involved there. You can't have a doctor 
patient interaction without there being an ethical interplay. It's certainly 
true on a larger level when you're dealing with populations: you can't 
have a science-population interaction without ethical repercussions. 1 
think the problem with many scientists is that they pretend that the y 
can." 
They identified an extensive mandate for ethicists and research ethics committees. 
Ethics committees would oversee research protocols and ensure that poorly designed 
studies involving race would not be approved. They would pay close attention to the 
needs of racial populations. Ethicists would also be charged with elaborating 
measures for the protection of the genetic information of research subjects; the y 
could also play an important role in ensuring that the harms done to racial 
populations once research results are published are minimal. Sorne respondents 
suggested that ethicists could play a role in ensuring the just distribution of 
pharmacogenomics products, by weighing on the decision to include racial 
populations in research and by lobbying to make these products affordable. Most 
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importantly, ethicists would bridge the gap between the researchers, decision-makers 
and the general public. 
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DISCUSSION 
The interviews offer a complex portrait of what could be coined the 
"doubled-edged" nature of pharmacogenomics research involving racial 
classification. This expression was indeed used by a majority of the respondents, 
who said it captured the cautious optirnism they felt was warranted by su ch research. 
Sensitized to racism and potential abuses, they felt conflicted by the sensitive nature 
of racially categorized research results. They sought to reconcile the scientific 
legitimacy of pharmacogenornics research involving race with a construct of race 
also rooted in a social and political context. However, we documented a great 
variability in the researchers' understanding of their own roles in potentially 
reinforcing genetic reductionism. The ambiguity sUITounding the notion of race 
threatens the practice of good science: how can we ascertain and interpret 
differential drug response by race when its very definition remains imprecise, fluid 
and time dependent? 
This study of researchers' views provides information that enriches the 
existing ELSI literature. Although the respondents demonstrated an awareness of 
the benefits and risks associated with genomics research, they were on the whole 
less familiar with the ethical concems sUITounding the scientific legitirnization of the 
notion of race. Their views on genetic differences between populations having 
implications for the prediction of disease, response to treatment and health care 
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outcomes reflect those of authors who argue in favour of using racial classification 
in genornics research (Burchard et al., 2003; Risch et al., 2002). The detailed 
explanations for these differences suggest an understanding of human genetic 
variation rooted in the distributions of alleles in populations according to 
geographical ancestry (Bamshad, 2005). They spoke of their concerns with using 
race as a flawed sUITogate for complex genetic and environmental factors, especially 
considering the level of adrnixture between populations. 
Consistent with the characterization of genomics researchers offered by 
others, the researchers nevertheless place a lot of emphasis on racial variation. In 
ascribing legitimacy to the use of racial classification in pharmacogenornics 
research, the researchers interviewed accept race as a significant scientific variable. 
An unintended consequence of this attitude towards the study of difference could be 
the reification of race in science and the reinscription of race as a biological notion 
(Duster, 2005; Lee, 2003). Many respondents had difficulty appreciating how their 
views appeared to invalidate their assertions that race is a social construction. 
Genornics researchers often invoke the social constructivism of race in their writings 
while at the same time emphasizing its biological meaningfulness (Reardon et al., 
2005). Our data highlights how this seerning incongruence in the remarks of 
researchers complexifies our understanding of their stance on the use of race in drug 
research. 
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This is illustrated by the fact that we did not anticipate that the researchers in 
our study would have a largely favourable opinion of the drug BiDil. In contrast to 
the criticisms levelled at the researchers and regulators who contributed to its 
deployment on the D.S. market, the issue of clinical utility dominates the study 
participants' appraisal much like it does for the researchers who put forth a defence 
of BiDil (Cohn, 2002; Franciosa et al., 2002). It should be noted that we did not 
expect the researchers to make a thorough scientific assessment of BiDil, which they 
conceded they could not provide without reviewing study protocols and regulatory 
documents pertaining to the drug. One possible explanation for this positive view 
lies in the fundamental and speculative nature of genomics research: as the 
researchers themselves expressed, a pharmaceutical treatment that can benefit 
patients represents a fitting culmination to years of work. 
In addition, our findings shed light on the proposed relationship between 
researchers' views on human genetic variation and their beliefthat a racial drug such 
as BiDil is warranted to improve health outcomes for racial populations. CUITent 
literature contends that promoting race-driven pharmacogenomics leads researchers 
to deemphasize the non-genetic and non-biological factors that contribute to health 
disparities (Fine, 2005; Lee, 2005). However, the researchers described themselves 
as mindful of accounting for the influences of culture, diet, socioeconomic status, 
and education, which they said were reflected in their own research. Another 
contrast emerges between the literature and the research results on the subject of 
whether racial pharmacogenomics will mitigate health disparities. Many 
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respondents believed that pharmacogenomics research involving race will help 
rectify inequalities by providing drugs targeted to subpopulations whereas ethicists 
and public health experts have argued the opposite (Fine, 2005; Lee, 2005). While 
they identified ethical issues related to access to drugs, the researchers were much 
less inclined to question wh ether devoting resources to pharmacogenomics research 
is ethically justified. 
We also found that the researchers were weIl versed in the risks and harms 
associated with genomics research. Individually, they identified many ethical issues 
that have been raised in the literature. The collective focus on potential racial 
discrimination and stigmatization suggests an awareness of the particularities of 
genomics research involving populations. It may be the case that genomics 
scientists have grown familiar with the implications for racial populations given the 
efforts by professional bodies to address them specifically. For instance, the Réseau 
de Médecine Génétique Appliquée released its 'Statement of Principles on the 
Ethical Conduct of Ruman Research Involving Populations', intended to shape the 
way in which genomics scientists conduct their research within Quebec's 
universities and institutions (RMGA, 2003). Perhaps surprisingly, the respondents 
singled out the fellow researchers as possible instigators of racism. An important 
insight from such remarks is that genomics researchers are privy to views, attitudes 
and practices within their community; as key informants, the uncomfortable truths 
they speak may be more likely to resonate than if they were spoken by non-
genomics researchers. 
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hnprovement of science literacy among the public was viewed as crucial to 
dispelling fallacies and rnisconceptions pertaining to race. The perception held by 
the researchers that the level of scientific knowledge and understanding by the 
public is inadequate confirm the findings presented in several studies (National 
Science Board, 2002, 2004). Moreover, individuals who hold prejudices were seen 
as susceptible to believe racist interpretations of research results. Sirnilarly to the 
data compiled by Matthews et al. (2005), the researchers welcome the public's 
involvement in discussions of the implications of genornics. In contrast to this same 
study however, the researchers say they do want ethicists to make pronouncements 
about or have a bearing on what research can and cannot be conducted. The positive 
view they have of ethicists is reflected in the extensive li st of duties the researchers 
delegate to them. While their role in overseeing research protocols and elaborating 
measures for the protection of research subjects is weIl defined, it is less clear how 
they would wield their influence to ensure the just distribution of pharmaceutical 
products destined for racial populations. Researchers remain sceptical of their own 
roles vis-à-vis ethics; trusting ethicists is seen as a way to remedy this shortfall. 
Further distinctions - albeit subtle - were revealed between genornics 
researchers and doctor researchers in their perceptions of the implications for 
patients. The researchers who were practicing physicians claimed that their contact 
with patients made them aware of the challenges in applying genomic discoveries to 
benefit patient health. This underscores the differences between values underlying 
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the obligations of a genomics researcher and the obligations of a doctor to a patient, 
distinctions which have been reflected in the academic division of research ethics 
and clinical ethics. 
Recommendations 
These data are a starting point in a reconsideration of the ethical framework 
applying to pharmacogenomics research involving race. As we move towards 
elaborating norms and guidelines, incorporating the realities of genomics researchers 
can inform the relationships between researchers and stakeholders necessary for 
their successful implementation. When considering the manner in which the 
fundamental principles elaborated in normative texts (e.g., respect for autonomy, 
non-maleficence and justice) should guide pharmacogenomics research, it will be 
important not to den y the saliency of race. Notwithstanding the debate between 
researchers surrounding its role in genomics, race remains a notion with tremendous 
social import. Further inclusion of racial populations would ensure that a wide range 
of viewpoints is taken into account. In addition to being consistent with the 
principles of reciprocity and accountability, this would allow researchers to engage 
in a dialogue likely to enrich their understanding of the ramifications of their work. 
In light of the complexity inherent to the interpretation of differential drug 
response, researchers must be careful not to overstate the benefits of race-specific 
pharmacogenomics. Researchers are indispensable to scientific literacy initiatives 
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yet must anticipate that members of the general public might not share their 
enthusiasm. Properly informing individuals while minimizing bias is thus necessary 
to preserve the integrity of pharmacogenomics research. Moreover, transparency on 
the part of the researchers can take on many forms including making explicit the 
scientific basis for using racial populations and communicating results in a timely 
manner. The researchers interviewed were insistent on the responsibility of 
researchers to con tribu te to the greater good and improve the health of the public. 
Consequently, research into 'individualized medicine' should be made to bene fit all 
populations, and complement health research in other disciplines. Finally, our 
findings highlight the importance of evaluating researchers' values and interests as 
weIl as the context in which pharmacogenomics research is practiced. 
Limitations 
The present study' s most significant limitation was the number of researchers 
interviewed. The smaller sarnple that is characteristic of qualitative research was not 
intended to be representative of the views of aIl genomics researchers; the results 
cannot be generalized. At the sarne, it is uncertain whether a greater number of 
respondents would have allowed for a more sophisticated insight into the views on 
pharmacogenomics and race. In a study on data saturation, Guest et al. posit that the 
sarnple size of Godard et al's qualitative study suffices in relation with the research 
objectives (Guest et al., 2006). In alilikelihood, interviews with researchers from 
populations other than the nine selected (e.g., researchers of French Canadian origin) 
55 
would have uncovered different preoccupations. It is to be expected that the views 
expressed by the respondents differed from those held by non-respondents. Members 
of the former group, as opposed to those who were solicited for participation but 
declined, may have been more aware of ethical implications or more likely to hold 
strong views about genornics researchers and their responsibilities to the broader 
community. 
Still, the ability to capitalize on the experiences of genornics researchers is a 
strength of qualitative research. A number of researchers expressed the opinion that 
their identification with a rninority population afforded them a unique perspective on 
the topics discussed during the interview. The interview transcripts revealed 
situations in which the tensions of the use of race categorization in research were 
shared by all researchers irrespective of their self-identified race. Sorne issues, such 
as the connotations of a racial prescription drug and the dissernination of race-
specifie research results to the greater public, were magnified or different for the 
researchers. They were nevertheless adamant in affirrning their distinct status as 
scientists. In their view, their level of education, profession and awareness of the 
issues set them apart from members of their respective cultural communities. The 
fact that their views are adrnittedly shaped by their identity as genornics researchers 
suggests a communitarian dimension to values. 
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CONCLUSION 
This study explored the ethical issues surrounding the use of racial 
classification in pharrnacogenomics research. The purpose of this master' s thesis is 
to identify the views of genomics researchers conceming the use of racial 
classification in pharrnacogenomics research. 
This descriptive exploratory study provides depth and detail regarding the 
views of genomics researchers regarding the ethical implications of 
pharrnacogenomics research involving race. The findings can be summarized as 
follows: the researchers were cautiously optimistic about such "doubled-edged" 
research. While placing a lot of emphasis on variation between racial populations, 
which they characterized as misunderstood by individuals and scientists alike, they 
demonstrated interest in understanding and studying human genetic variation. They 
had a favourable view of race-specific therapeutics and believed that 
pharrnacogenomics would improve health outcomes for racial populations in a 
context of health disparities. Sensitized to racism and potential abuses, they 
nevertheless feH conflicted by the sensitive nature of racially categorized research 
results. 
The recommendations fonnulated in this study have consequences for 
subjects of research, the professional practice of researchers as weIl as for efforts to 
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increase reciprocity between researchers and the public. Further inclusion of racial 
populations will be necessary to evaluate whether ethical principles as the y have 
been applied in existing guidelines respond to the challenges arising from the use of 
race. The importance of not denying the saliency of race emerges as a manifestation 
of non-maleficence: researchers must be careful not to overstate the benefits of race-
specific pharmacogenomics. The study by genomics researchers into inherited drug 
response would also benefit from interdisciplinary research. The contribution of 
social scientists could help our understanding how the notion of race is impacted by 
pharmacogenomics research involving race, just as the work of medical historians 
can help situate CUITent developments within a historical context; meanwhile, 
research in the fields of pharmacology and pharmacoepidemiology remains essential 
for the delivery of real world effectiveness and positive health outcomes. The 
contribution of scientists to scientific literacy initiatives would ensure that the public 
is properly informed, along with a commitment to transparency in genomics 
research. 
The views of researchers are likely to be fundamentally necessary in 
addressing the pervasiveness of race in genomics and other biomedical research. 
However, our understanding of how to situate these views within a society-wide 
discourse needs to be enriched. Describing genomics researchers' views on how 
they conceive of their role in the process by which race is either accepted or 
discarded as a biological notion provides an important area of future research. 
Because ethical norms and guidelines remain inextricable from the work of 
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researchers, we must continue to examine the perceptions of researchers towards 
research ethics. Research into the views on pharmacogenomics research involving 
race of other researchers, particularly epidemiologists and public health experts, 
would prove a fitting complement to the insights gained from interviewing genomics 
researchers. 
Most importantly, thinking critically about the about the implications of 
racial research requires sustained investigation into the views of the public. In light 
of our findings that identification with a cultural community or racial population 
informs perceptions, it will be revelatory to seek out the interests and concems of 
minority populations. Finding out what they think about research involving race can 
generate knowledge helpful to the conduct of research (e.g., research needs, 
recruitment initiatives) as weB as to the elaboration ofhealth policy (e.g., technology 
assessments, public funding of prescription drugs). And as the researchers 
interviewed held strong views about the public, it will be similarly important to 
engage individuals in a discussion of their perceptions of genomics researchers and 
of the scientific community. In sum, on the issue of race in genomics and 
pharmacogenomics research, bioethical enquiry should forge ahead with strong 
theoretical work that is informed by the realities of stakeholders. 
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ix 
RESEARCH QUESTIONNAIRE 
LA CONSULTATION DE COMMUNAUTÉS CULTURELLES ENVERS LA 
CRÉATION DE BANQUES DE DONNÉES GÉNOMIQUES À GRANDE 
ÉCHELLE: UNE ANALYSE DES INTÉRÊTS ET DES VALEURS 
Introduction 
Tel qu'expliqué dans la lettre d'invitation qu'on vous a envoyée, le Groupe de 
recherche en éthique biomédicale de l'Université de Montréal vous propose de 
participer à un projet de recherche visant à consulter diverses communautés 
culturelles envers la création de banques de données génomiques/génétiques à 
grande échelle (biobanques). Ce projet se fait en collaboration avec l'Institut 
interculturel de Montréal et l'équipe Culture et migration de la Direction de santé 
publique de Montréal. 
Actuellement, on assiste à la création de plusieurs biobanques, telles le projet 
CARTaGENE, l'Initiative sur la santé des Canadiens à tous les stades de la vie 
(ISCVS), ou l'Enquête canadienne sur les mesures de la santé (ECMS) de 
Statistique Canada. Ces biobanques nécessitent de recruter de larges cohortes 
d'individus: 50 000 Québécois pour le projet CARTaGENE, 50 000 Canadiens pour 
l'ISCVS, et 5 000 Canadiens pour l'ECMS. Un tel recrutement demande des 
connaissances approfondies sur les représentations sociales de ces projets et de leur 
approche. Par exemple, quels sont les risques perçus par le public? Les perceptions 
sont-elles les mêmes dans tous les groupes de la société, ou pour ce qui nous 
intéresse ici, dans les diverses communautés culturelles? 
Une étude des intérêts et des valeurs est primordiale afin de développer des 
approches scientifiques valides et pertinentes tenant compte de divers enjeux 
éthiques sociaux et culturels de notre société. 
Biobanques 
Donc, quelle est votre perception de ces projets de biobanques? 
Au Québec ou au Canada, croyez-vous qu'une banque de données génomiques ou 
génétiques à l'échelle de la population aura des aspects positifs/négatifs sur votre 
communauté? 
Participation 
Vous-même, est-ce vous participeriez à un tel projet? Selon-vous, est-ce que les 
membres de votre communauté y participeraient également? 
x 
Qu'est ce qui vous inciterait à (ne pas) y participer (Vérifier en plus de l'importance 
scientifique: utilisation spécifique, retour d'information, anonymat, destruction 
possible, utilisation par MD, famille ... )? 
Et les membres de votre communauté? 
Collecte et stockage d'échantillons 
Est-ce que vous seriez prêt à donner un échantillon de sang? Selon-vous, est-ce que 
les membres de votre communauté seraient à l'aise avec le processus de 
prélèvement? Quelles mesures de protection devraient être mise en place? 
Est-ce que vous consentiriez à ce que vos données génétiques soient conservées pour 
plusieurs années? Et les membres de votre communauté? Pour quelles raisons? 
Quels bénéfices attendriez-vous de votre participation à une biobanque? Et votre 
communauté? 
Enjeux éthiques et sociaux 
Un autre projet international de biobanque, le projet HapMap, a montré grâce à 
l'étude des échantillons d'ADN, qu'il y avait très peu de différences génétiques 
(0,1 %) entre les Mricains et les Nord-Américains ou entre ces derniers et les 
Asiatiques. 
Si vous participiez à un projet de biobanque, quel impact l'information génétique 
issue de votre échantillon et des échantillons de vos concitoyens pourrait-elle avoir 
sur la façon dont l'origine et l'histoire de votre communauté est définie? 
Croyez-vous que les résultats de recherche provenant de biobanques pourraient avoir 
un impact sur la stigmatisation ou la discrimination envers votre communauté? Dans 
quel sens? 
Y-a-t-il des maladies ou des conditions héréditaires (d'ordre génétique) qui touchent 
votre communauté en particulier? 
L'existence de ces conditions héréditaires a-t-elle engendré des problèmes de 
discrimination ou de stigmatisation pour votre communauté? D'autres problèmes 
(ex: eugénisme)? 
Au contraire, croyez-vous que votre communauté bénéficie actuellement de 
traitements médicaux ou d'interventions particulières grâce aux recherches en 
génétique? 
Race et ethnicité 
xi 
Selon vous, quelle importance la race/ethnicité occupent-elles dans la manière dont 
votre communauté se perçoit et se définit? 
Quel rôle joue la génétique dans votre conception de race/ethnicité? 
Religion 
Croyez-vous que vos croyances religieuses ou spirituelles influencent vos attitudes 
envers la génétique? 
Quel rôle occuperait la religion ou la spiritualité dans votre décision de participer ou 
non à un projet de biobanque? 
Pharmacogénomique 
Est-ce que vous participeriez à un projet de biobanque si l'information recueillie 
servait à la recherche et au développement de médicaments? 
RiDil, dont la vente aux Etats-Unis a été autorisée en juin 2005, est le premier 
médicament à prescription raciale. TI a été conçu pour traiter les insufficances 
cardiaques spécifiquement chez les afro-américains. 
Est-ce que vous seriez disposé à prendre un médicament conçu pour traiter 
_____ (condition génétique identifiée par répondant) si ce produit était destiné 
«spécifiquement» pour votre communauté? 
Croyez-vous qu'un tel produit pharmacogénomique aura des aspects 
positifs/négatifs (sociaux et médicaux) sur votre communauté? 
Herceptin est un médicament derivé de la pharmacogénomique destiné au 15%-30% 
des patientes atteintes d'un type de cancer du sein aggressif: un test génétique sert à 
identifier les femmes qui en bénificieront. Au Québec, on a longtemps hésité à offrir 
Herceptin à toutes les femmes éligibles parce qu'il coûte très cher ($50 000). 
Croyez-vous que le gouvernement serait prêt à subventionner le coût de produits 
pharmacogénomiques destinés spécifiquement à votre communauté? Croyez-vous 
que l'industrie pharmaceutique serait prête à investir dans la recherche et le 
développement de tels médicaments? 
Culture 
En conclusion, pensez-vous que votre opinion reflète généralement celle de votre 
communauté? 
Croyez-vous que vos perceptions de la génétique témoignent de valeurs propres à 
votre communauté? 
Quels sont les éléments qui rendent votre communauté distincte des autres? 
Par quels moyens pouvez-vous, ainsi que vos concitoyens, être plus informés et 
impliqués dans un projet de biobanque? 
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